In 4‐month‐old AD mice, LysM‐Cre altered neither Mapk14 transcription nor p38‐MAPK protein in CD11b+ brain cells, but decreased Mapk14 transcription by 88% in CD11b+ blood cells (Figure S1b–e). This evidence concerns the gene MAPK14 and Alzheimer disease.